Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79

The mutant Myd88L265P protein promotes lymphoma cell survival in diffuse large B-cell lymphoma (DLBCL) by activating NF-κB via Irak-4. On the other hand, constitutively activated signaling of the B-cell receptor (BCR), encoded by CD79A/B , activates NF-κB via Bruton’s tyrosine kinase (Btk).